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ndoproteolysis of the 
 
 
 
-amyloid precursor protein
(APP) by 
 
 
 
- and 
 
 
 
-secretases generates the toxic
amyloid 
 
 
 
-peptide (A
 
 
 
), which accumulates in the
brain of Alzheimer’s disease (AD) patients. Here, we es-
tablished a novel approach to regulate production of A
 
 
 
based on intracellular expression of single chain anti-
bodies (intrabodies) raised to an epitope adjacent to the
 
 
 
-secretase cleavage site of human APP. The intrabodies
rapidly associated, within the endoplasmic reticulum (ER),
with newly synthesized APP. One intrabody remained as-
sociated during APP transport along the secretory line,
E
 
shielded the 
 
 
 
-secretase cleavage site and facilitated the
alternative, innocuous cleavage operated by 
 
 
 
-secretase.
Another killer intrabody with an ER retention sequence
triggered APP disposal from the ER. The ﬁrst intrabody
drastically inhibited and the second almost abolished
generation of A
 
 
 
. Intrabodies association with speciﬁc
substrates rather than with enzymes, may modulate intra-
cellular processes linked to disease with highest speciﬁcity
and may become instrumental to investigate molecular
mechanisms of cellular events.
 
Introduction
 
Aging is a major risk factor for Alzheimer’s disease (AD) and
the number of AD patients will increase in the near future. For
this reason, therapeutic treatments against this devastating
disease  are urgently sought for (Hardy and Selkoe, 2002;
Dodel et al., 2003; Cummings, 2004; Mattson, 2004; Tanzi et
al., 2004). The amyloid hypothesis holds that generation and
deposition of amyloid 
 
 
 
-peptide (A
 
 
 
) are key events driving
neurodegeneration in AD (Glenner and Wong, 1984). Immuno-
therapy involving injection of synthetic A
 
 
 
 aggregates to elicit
neutralizing and aggregate-breaking antibodies and passive A
 
 
 
immunization showed promising results in delaying cognitive
decline (Younkin, 2001; Haass, 2002), but also underscored the
risk of side effects (Pfeifer et al., 2002; Nicoll et al., 2003).
Other approaches aim at reducing A
 
 
 
 generation by inhibiting
the secretase activities. 
 
 
 
-Secretases cleave several substrates
and their inactivation appears to interfere with physiologically
important signaling pathways (Haass, 2004), but 
 
 
 
-secretase
remains an obvious therapeutic target because its activity can
fully be removed in mice by knocking out BACE (
 
 
 
-site APP
cleaving enzyme) without any obvious toxicity (Luo et al.,
2001; Ohno et al., 2004). Inhibitors of BACE are under active
study, but the development of specific, cell-permeable drugs
that penetrate into the brain remains a challenging task (Kahle
and De Strooper, 2003).
Here, we propose a novel approach to control A
 
 
 
 pro-
duction in vivo. The approach is based on intracellular expres-
sion of single chain antibodies (intrabodies; Biocca et al.,
1990; Bird et al., 1988; Huston et al., 1988; Marasco and Dana
Jones, 1998; Lobato and Rabbitts, 2004; Stocks, 2004) that
interfere with pathologic endoproteolysis by binding close to
the 
 
 
 
-secretase cleavage site of huAPP (Fig. 1). One intrabody
associated within the ER with newly synthesized 
 
 
 
-amyloid
precursor protein 
 
(
 
APP). Association persisted during APP trans-
port along the secretory line, protected APP from 
 
 
 
-secretase
cleavage and favored the alternative cleavage by 
 
 
 
-secretase.
This resulted in decreased production of the toxic A
 
 
 
 peptide
and increased production of P3. Another intrabody carrying a
carboxy-terminal ER retention signal caused quantitative ER
retention and slow disposal of APP, thereby virtually abolishing
A
 
 
 
 production.
 
Results and discussion
 
The monoclonal antibody 
 
 
 
1 (Paganetti et al., 1996) specifically
binds to the EFRH tetrapeptide adjacent to the 
 
 
 
-secretase
cleavage site of huAPP (Fig. 1, at position A
 
 
 
3-6
 
). 
 
 
 
1 was used
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as template for preparation of two intrabodies named sFv
 
 
 
1
and sFv
 
 
 
1-KDEL. sFv
 
 
 
1 consists of the light and heavy chain
variable regions of 
 
 
 
1 (132 and 120 residues, respectively)
covalently linked by a GGGGS pentapeptide repeated three
times. sFv
 
 
 
1-KDEL is a variant of the same intrabody carrying
the SEKDEL carboxy-terminal residues of BiP/GRP78 to con-
fer ER retention (Munro and Pelham, 1987). The native signal
sequence of the light chain was maintained to target the intra-
bodies to the ER lumen. Liquid chromatography mass spec-
trometry of secreted sFv
 
 
 
1 expressed in human embryonic kid-
ney 293 (HEK) cells revealed that the signal peptide was
removed at the consensus site similar to the original 
 
 
 
1 anti-
body (unpublished data).
We first determined if sFv
 
 
 
1 maintained the capacity of
the 
 
 
 
1 template to associate with huAPP when expressed intra-
cellularly. HEK cells were transfected for expression of the Swed-
ish variant of huAPP (Mullan et al., 1992) with or without
sFv
 
 
 
1. 1 d after transfection, cells were metabolically labeled
with 
 
35
 
S-methionine and cysteine, chased for 10 min or 2 h, and
detergent solubilized. Labeled huAPP was immunoprecipitated
from cell lysates with specific antibodies. In mock-transfected
cells, huAPP was the only labeled protein isolated (Fig. 2 A,
lanes 1 and 2). After a 10-min chase APP is immature (APP
 
i
 
;
M
 
r 
 
  
 
120 kD) in the ER as shown by EndoH sensitivity of its
single N-linked glycan (Fig. 2 B). After a 2-h chase most of huAPP
was released from the ER and the 
 
N
 
-glycan became EndoH resis-
tant (Fig. 2 B). Maturation of huAPP (APP
 
m
 
; M
 
r 
 
  
 
130 kD) also
involves tyrosine-sulfation and 
 
O
 
-glycosylation resulting in higher
M
 
r
 
 (Weidemann et al., 1989). In cells also expressing sFv
 
 
 
1, the
intrabody (M
 
r 
 
  
 
26 kD) coprecipitated with APP
 
i
 
 after a 10-min
chase (Fig. 2 A, lane 3) and association persisted through the
chase (lane 4). Monitoring kinetics of association revealed that
the half-time for formation of the intracellular sFv
 
 
 
1-huAPP
complex was 11 min (Fig. 2 C) and that association between
sFv
 
 
 
1 and huAPP did not prevent huAPP maturation (Fig. 2 A,
lane 4 and Fig. S1, available at http://www.jcb.org/cgi/content/
full/jcb.200410047/DC1). The specificity of sFv
 
 
 
1 for huAPP
was confirmed by the substantial reduction in the amount of
sFv
 
 
 
1 coprecipitated with a variant of APP characterized by a
EF
 
G
 
H versus EF
 
R
 
H mutation in the 
 
 
 
1 epitope (Fig. 2 A,
RGAPP). Also the parental antibody 
 
 
 
1 has strongly decreased
affinity for this epitope present in mouse APP.
Next, we coexpressed huAPP with sFv
 
 
 
1-KDEL to deter-
mine first if this intrabody maintained the capacity to associate
with APP, and second to establish if appending an ER-retention
sequence to an APP-targeted intrabody also caused retention of
huAPP. Cells were metabolically labeled and chased for 10 min
and 3 h. sFv
 
 
 
1-KDEL had slower electrophoretic mobility than
sFv
 
 
 
1 (Fig. 3 A). It rapidly associated with newly synthesized
huAPP as shown by coimmunoprecipitation after a 10-min
chase (Fig. 3 A, lane 3) and association persisted through the
chase (Fig. 3 A, lane 4). Unlike sFv
 
 
 
1, however, association of
sFv
 
 
 
1-KDEL with huAPP prevented export of the latter from
Figure 1. Scheme of APP processing by the secretases. APP is a type I
transmembrane protein with a single hydrophobic domain for membrane
retention. The amyloidogenic processing of APP produces the  -amyloid
peptide (A ) through sequential cleavages by BACE at the  -site and by
 -secretase. Shedding of the APP ectodomain occurs through redundant
proteolytic events at the cell surface ( -cut) or in endosomes ( -cut) by the
secretases. The Swedish mutation at the  -site strongly favors BACE cleavage
of APP on route to the cell surface. The 40 aa sequence of A  is also depicted
(bold letters) as well as the 3 aa exchanged in murine A  (normal fonts).
The EFRH epitope of the  1 antibody is mutated to EFGH in RGAPP.
Figure 2. Specific binding of sFv 1 to human APP in cells. (A) HEK cells
were transfected for expression of huAPP (lanes 1 and 2), sFv 1 and
huAPP (lanes 3 and 4), or sFv 1 and RGAPP (lanes 5 and 6). After meta-
bolic labeling with 
35S-amino acids and chasing with unlabeled amino
acids, huAPP and RGAPP were immunoprecipitated from cell extracts with
a carboxy-terminal APP antibody. When present, sFv 1 associates and
coprecipitates with HuAPP but not with RGAPP. APPi denotes the immature
and APPm denotes the mature form of APP. (B) Analysis on 8% SDS PAGE
better visualizes APP maturation and EndoH sensitivity. At 10 min labeled
APPi is still EndoH sensitive; but after 2 h APP is released from the ER and
APPm becomes EndoH resistant and shows increased Mr upon N-glycan
modification, tyrosine-sulfation, and addition of O-glycans. (C) Kinetics of
APP:sFv 1 association were determined by coimmunoprecipitations and
plotted as a function of the maximal amount of sFv 1 coprecipitated with
APP. The position of Mr markers of 200, 116, 97, 66, 45, and 32 kD is
shown with thin lines. 
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the ER. In fact, the molecular weight of APP did not increase
with progression of the chase (Fig. 3 A, lanes 3 and 4) and the
protein failed to acquire EndoH resistance or other posttransla-
tional modifications even after 3 h (Fig. 3 A, EndoH).
Cytochemical analysis by indirect immunofluorescence
revealed that part of huAPP colocalized with the ER marker
calnexin (Cnx) and part of it stained clustered regions free of
Cnx (Fig. 3 B, squares, panels 1 and 2) but stained with an anti-
body to the Golgi marker Giantin (Fig. 3 B, panels 3 and 4).
Note that all cells are labeled with the markers but only trans-
fected cells are positive for anti-APP. ER and Golgi localiza-
tion is expected for APP, a secretory protein synthesized in the
ER and transported for maturation along the secretory pathway
(Weidemann et al., 1989). Expression of sFv
 
 
 
1 did not affect
the intracellular localization of huAPP, which colocalized in
part with Cnx (Fig. 3 B, panels 5 and 6) but was also in perinu-
clear clusters stained with Giantin (Fig. 3 B, panels 5, 7, and 8).
On the other hand, expression of sFv
 
 
 
1-KDEL caused reten-
tion of huAPP in the ER as shown by exclusion of APP from
Giantin-containing structures (Fig. 3 B, panels 9–12). Thus, we
generated one intrabody (sFv
 
 1) that associated with APP in
the ER lumen and remained associated with it during transport
along the secretory line. A second intrabody (sFv 1-KDEL)
was equally efficient and fast to associate with APP, but pre-
vented exit of the target protein from the ER. sFv 1-KDEL ac-
tually acted as a killer intrabody because it triggered slow dis-
posal of newly synthesized APP in a process that was delayed
by MG132, an inhibitor of the cytosolic proteasome (Fig. 3 C).
We next determined if intracellular association of sFv 1
and of sFv 1-KDEL with APP affected secretase-mediated en-
doproteolysis resulting in the shedding of the ectodomain of
this type I membrane protein. Cells coexpressing huAPP and
sFv 1 or sFv 1-KDEL were metabolically labeled and chased
for 10 min or 2 h. To analyze protein secretion, conditioned
media were harvested, boiled in sample buffer and analyzed by
SDS PAGE. Because of CMV-driven expression, labeled sAPP
(and sFv 1) are the major secretory products of transfected
HEK cells. After 10 min, no labeled ectodomain was secreted
(Fig. 4 A, lanes 1, 3, and 5; Fig. S1) as the labeled proteins are
still folding in the ER. After a 2-h chase, ectodomain shedding
of labeled huAPP had occurred in mock-treated cells (Fig. 4 A,
lane 2; Fig. S1). Coexpression of sFv 1 significantly reduced
(Fig. 4 A, lane 4; Fig. S1), and coexpression of sFv 1-KDEL
virtually abolished secretase-mediated release of huAPP from
cells (Fig. 4 A, lane 6). APP with the mutated  1 epitope
served again as specificity control because coexpression of
sFv 1 did not reduce release of the RGAPP ectodomain in the
extracellular media compared with controls (Fig. 4 C).
Figure 3. Intracellular localization and fate of huAPP
coexpressed with sFv 1 or with sFv 1-KDEL. (A) Cells
expressed huAPP and sFv 1 or sFv 1-KDEL. Both intra-
bodies associates and coprecipitates with huAPP using a
carboxy-terminal antibody to APP. In the presence of
sFv 1, APPm at the end of the 3-h chase has higher Mr
than newly synthesized APPi (10 min). In contrast, sFv 1-
KDEL impairs maturation of APP, no Mr shift is observed
and APPi remains EndoH sensitive. (B) Indirect immuno-
fluorescence was performed with an antibody to APP
(transfected cells in panels 1, 3, 5, 7, 9, and 11) and to
Cnx to visualize the ER (all cells in panels 2, 6, and 10)
or Giantin to visualize the Golgi (panels 4, 8, and 12). In
the presence of sFv 1-KDEL (panels 9–12), APP and Cnx
colocalizes. In sFv 1 (panels 5–8) or mock-transfected
cells (panels 1–4), APP is detected in the ER and in the
Golgi. (C) Immature APP retained in the ER by sFv 1-
KDEL is degraded with a t1/2 of  2 h; APP disposal is
partially inhibited by the proteasomal inhibitor MG132.JCB • VOLUME 168 • NUMBER 6 • 2005 866
Labeled sFv 1 was secreted in the conditioned medium
(Fig. 4, A and C, lane 4), whereas virtually no labeled sFv 1-
KDEL was detected extracellularly (Fig. 4 A, lane 6), as ex-
pected for a polypeptide carrying an ER retention signal. Part
of the secreted sFv 1 was associated and coprecipitated with
the secreted huAPP (Fig. 4 B, lane 4) but not with the control
protein RGAPP (Fig. 4 C, lane 8). Thus, the complex between
the intrabody and huAPP was maintained during secretion and
after shedding. From the data described above, we concluded
that uncomplexed sFv 1 was also released from cells. This is
of interest and might have beneficial consequences in case of a
therapeutic application of our approach because recognition
of the EFRH epitope proved essential for antibodies able to
prevent formation or to disassemble preexisting A  plaques
(Frenkel et al., 1998; Pfeifer et al., 2002). Moreover, passive
immunization may rapidly reverse behavioral deficits in mice
(Dodart et al., 2002). To establish if in situ release of intrabod-
ies targeted to A  exerts protective and/or therapeutic activity
awaits further experimentation in an animal model for the dis-
ease. Thus, in a series of several independent experiments
summarized in Fig. 4 D, we proved that by associating close to
the  -secretase cleavage site, sFv 1 inhibited by  60% the
processing and release of the Swedish variant of APP. Addi-
tion of a SEKDEL-retention signal led to production of a killer
intrabody that retained newly synthesized APP in the ER pre-
venting secretase processing and eventually leading to slow
degradation of APP.
The endoproteolysis of APPSwedish consists mainly in
sequential cleavages by  - and  -secretase releasing the solu-
ble APP ectodomain and the toxic A  peptide. A minor alter-
native endoproteolysis initiated by  -secretase releases the sol-
uble APP ectodomain and the peptide P3 (Fig. 1). Therefore,
we next determined how coexpression of sFv 1 or sFv 1-
KDEL affected production of the APP metabolites A  and P3.
APP-derived peptides produced by HEK cells were identified
independently by matrix-assisted laser desorption ionization
time of flight mass spectrometry (Wang et al., 1996; unpub-
lished data). Here, we determined the peptides by combining
immunoprecipitation and immunoblotting with two well-char-
acterized antibodies to the carboxy terminus of A  (Paganetti
et al., 1996) and electrophoretic comigration with synthetic
peptides (Fig. 5).
As demonstrated above using metabolic labeling, steady-
state analysis of cell lysates by Western blot confirmed that
sFv 1 did not interfere with APP maturation (Fig. 5 A, lanes 1
and 2). In contrast, sFv 1-KDEL strongly impaired APP matu-
ration (Fig. 5 A, lane 3). Overexpression of APPSwedish pro-
duced abundant A  as expected for this substrate efficiently
processed by  -secretase (Fig. 5 B, lane 1). Consistent with the
Figure 4. Consequences of sFv 1 and of sFv 1-KDEL expression on APP
processing and release in the extracellular medium of the APP
ectodomain. (A) 15  l of conditioned medium (total was 1.5 ml) were
boiled in sample buffer and analyzed in SDS-PAGE for determination of
radiolabeled APP-ectodomain (sAPP) release from cells at 2 h (lane 2).
Coexpression  of sFv 1 reduces sAPP release from cells (lane 4) and
sFv 1-KDEL virtually abolishes release of the APP ectodomain (lane 6).
(B) The same samples analyzed in A were immunoprecipitated with an APP-
specific antibody to demonstrate sAPP:sFv 1 association. Only a fraction of
secreted sFv 1 coprecipitates with sAPP (compare the relative ratio sAPP
vs. sFv 1 in A and B, lanes 4). (C) Coexpressing of sFv 1 does not lower
secretion of the RGAPP ectodomain (lanes 2 and 4, cond. media; lanes 2
and 4, anti-APP) and sFv 1 does not associate with RGAPP as shown by
lack of coprecipitation (lane 4, anti-APP). (D) sAPP secretion was quantified
in a series of five independent experiments. Error bar represents SD.
Figure 5. Consequences of sFv 1 and of sFv 1-KDEL expression on
production of A  and P3. (A) Western blot analysis of cell lysates with a
carboxy-terminal APP-antibody visualizes immature (APPi) and mature
(APPm) full-length APP at steady state. Maturation of HuAPP and RGAPP is
not affected by sFv 1 when compared with mock conditions. On the other
hand, sFv 1-KDEL fully retains HuAPP in the APPi form, but shows much
lower affinity for the mutated EFGH epitope of RGAPP. (B) A  and P3
were identified according to their electrophoretic mobility using synthetic
peptides after immunoprecipitation and Western blot analysis using two
carboxy-terminal A -specific antibodies. Secretase-mediated endoproteolysis
of APPSwedish mainly results in production of A  (lane 1). Association of
sFv 1 close to the  -secretase cleavage site substantially reduces production
of A  (lane 2), whereas sFv 1-KDEL virtually abolishes production of A 
(lane 3). The intrabodies have no effect on A  generation when the RG
mutant of APP is expressed (lanes 4–6). Overexposition of gel (bottom)
better visualizes the metabolite P3, and shows that sFv 1 lowers A ,
whereas favoring  -secretase–mediated cleavage resulting in the innocuous
P3 peptide (lane 2).INTRABODIES TO REDUCE A  PRODUCTION • PAGANETTI ET AL. 867
effects observed for the ectodomain shedding, A  generation
was lowered by coexpression of sFv 1 (Fig. 5 B, lane 2) and
virtually prevented by sFv 1-KDEL (Fig. 5 B, lane 3). In con-
trast, sFv 1 did not affect cleavage of the RGAPP carrying the
point mutation in the sFv 1 epitope (Fig. 5, A and B, lane 5)
and sFv 1-KDEL slightly affected RGAPP maturation (Fig. 5
A, lane 6) and did not affect significantly the production of A 
(Fig. 5 B, lane 6).
Analysis of the ratio A  (Mr   4 kD) versus P3 (Mr   3
kD) produced in mock-transfected cells and in cells expressing
sFv 1 (Fig. 5 B, longer exposure, lanes 2 and 3) revealed that
sFv 1 augmented to a certain extent P3, i.e., shifted APP
cleavage from the  - to the  -site. Thus, association of intra-
bodies to a sequence adjacent to the  -secretase cleavage site
interfered with the amyloidogenic processing of huAPP by the
 -secretase as determined by reduction of release from cells of
the APP ectodomain and A . In contrast, the innocuous cleav-
age by  -secretase was slightly favored as shown by increased
production of P3.
In summary, we engaged the cellular protein factory, the
ER, to produce therapeutic agents inhibiting production of A .
By rapidly associating with newly synthesized APP and by es-
corting it during intracellular transport, sFv 1 shielded APP
from the pathologic  -secretase–mediated cleavage. By ap-
pending an ER-retention sequence, we generated an intrabody
that retained APP in the ER strongly impairing A  production.
Intrabodies are derived from the virtually unlimited rep-
ertoire of antibodies. Unlimited is, therefore, the choice of tar-
get molecules. The use of specific intrabodies allowed inter-
vention in an enzymatic process leading to a human disease
by targeting the substrate, rather than the modifying enzyme
whose activity is at the origin of the disease. By avoiding direct
intervention on the enzyme, liabilities for side effects that may
be triggered when the enzyme of interest is involved in other
physiologic processes are lowered. Our data present a “proof of
principle” for an intervention with highest selectivity in patho-
physiologic processes in disease.
Materials and methods
Cell lines and transient transfections
HEK cells were grown in DME supplied with 10% FCS, penicillin, and
streptomycin (GIBCO BRL). For transfections, cells plated at 90% conflu-
ency were transfected with expression plasmids using Lipofectamine 2000
(GIBCO BRL) according to the manufacturer’s instructions for adherent
cells. For cotransfections, plasmids for APP and intrabody expression were
used in a 1:3 ratio. This DNA ratio makes it unlikely that cells expressing
only APP are present in our cultures.
Metabolic labeling, preparation of cell extracts, immunoprecipitation, and 
EndoH treatments
17 h after transfections cells were starved for 30 min in Met/Cys free me-
dium, pulsed for 10 min with 150  Ci/ml 
35S-Met/Cys in starvation me-
dium and chased with DME supplemented with 5 mM of cold Met/Cys.
Cell extracts were prepared by solubilization in 800  l/dish ice-cold 2%
CHAPS in Hepes buffer saline, pH 6.8, containing 20 mM ice-cold N-eth-
ylmaleimide and protease inhibitors (HBS). Postnuclear supernatants were
prepared by a 10-min centrifugation at 10,000 g and analyzed by reduc-
ing SDS-PAGE as described in Molinari et al. (2003). 12% polyacryl-
amide gels were used, with the exception of 8% gels in the EndoH analy-
sis (Figs. 2 and 3) and for Fig.5 A. Analysis of A  and P3 in Fig. 5 B was
done on 13% Tris/bicine gels (Klafki et al., 1996). Immunoprecipitations
were performed using antibodies and protein A beads (Sigma-Aldrich)
and 1–4-h incubations in a cold room. The immunoprecipitates were
washed three times with HBS/0.5% CHAPS and resuspended in sample
buffer for SDS-PAGE. Gels were exposed to BioMax (Kodak) films and
scanned with an Agfa scanner. For EndoH treatment, APP was immuno-
precipitated from the cell extracts with specific antibody and denatured
before incubation for 1 h at 37 C with 1 mU of EndoH (Roche Molecular
Biochemicals). For immunoblotting, protein in cell extracts or immunopre-
cipitates were separated by reducing SDS-PAGE and transferred to Immo-
bilon P membranes (Millipore) before blotting with specific antibodies (Pa-
ganetti et al., 1996).
Indirect immunofluorescence microscopy
For indirect immunofluorescence, HEK cells were plated for 24 h on alcian
blue-treated glass coverslips, washed twice with PBS, and fixed at RT for
20 min in serum-free medium Hepes containing 3.7% formaldehyde. Cells
were washed twice in serum-free medium Hepes, twice with PBS and per-
meabilized with 0.05% saponin (PS) for 15 min. Cells were incubated
with primary antibody diluted in PS for 45 min, washed 15 min with PS,
then incubated with conjugated secondary antibody diluted in PS for 30
min. Cells were rinsed with PS and water and mounted in Mowiol.
Microscopic images were collected at RT using a microscope
(model E-800; Nikon) equipped with a 60 /1.4 Plan Apo objective, filter
cubes for CFP and YFP fluorescence, and a camera (Q-Imaging), con-
trolled by Openlab 3.5 software. Image cropping and adjustment were
accomplished using Photoshop (Adobe).
Online supplemental material
Fig. S1 shows Kinetics of APP maturation and disappearance from cells
(Intracellular) and of secretion of soluble APP (sAPP, extracellular). Longer
persistence of the mature form of APP (APPm, top gel, panel on the right) in
cells expressing sFv 1 is a further indication that intrabody coexpression
interferes with shedding of the APP ectodomain. This is proved by the
lower amount of sAPP in the extracellular media (bottom panel compare
labeled sAPP in lanes 4 vs. 5). Online supplemental material is available
at http://www.jcb.org/cgi/content/full/jcb.200410047/DC1.
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